Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2768)	2/1/2001 5:04:27 PM
From: nigel bates	Read Replies (2) \| Respond to of 52153

All I could come up with for now (& I really can't be bothered to take the exercise any further...). There is clearly no suggestion, express or implied, of any connection between Lehman Brothers' analyst & equity offerings... Nov. 10 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX - news) announced today the pricing of its public offering of 70 million shares of common stock at $39.75 per share.... Morgan Stanley Dean Witter and Merrill Lynch & Co. are the joint lead managers for the offering. Credit Suisse First Boston, Lehman Brothers, Banc of America Securities LLC, Bear, Stearns & Co. Inc. and Robertson Stephens are co-managers of the offering. Oct. 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI - news) today announced that it has priced a public offering by the Company of 11,000,000 shares of its Common Stock at a price of $75.00 per share. Gross proceeds totaled approximately $825 million. The offering was led by Credit Suisse First Boston and co-managed by Goldman, Sachs & Co., Lehman Brothers, CIBC World Markets, J.P. Morgan & Co. and Dain Rauscher Wessels. April 7, 2000--Corixa Corporation (Nasdaq:CRXA - news) today announced the sale of 1,900,000 primary shares of Corixa Common Stock at a price of $32 per share... The shares were offered by an underwriting group led by Warburg Dillon Read LLC, Lehman Brothers Inc., Prudential Vector Healthcare Group, a unit of Prudential Securities, and Pacific Growth Equities, Inc. Oct. 6 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - news) today announced that it had entered into an agreement to sell 11 million shares of its common stock at a price of $64 per share in a public offering. The net proceeds of the offering will be used for working capital and other general corporate purposes. The Company has granted the underwriters an option to purchase up to 1.65 million additional shares to cover over-allotments. Goldman, Sachs & Co. and Morgan Stanley Dean Witter jointly managed the offering, which was co-managed by Robertson Stephens, Inc. and Credit Suisse First Boston Corporation. March 1, 2000--PE Corporation today announced the public offering of 3.8 million shares of Celera Genomics common stock at a price of $225.00 per share. The underwriters also have an option to purchase up to an additional 570,000 shares of Celera Genomics common stock to cover over-allotments. The net proceeds to Celera as a result of the offering, after fees and expenses, are expected to be $820 million. The shares, all of which were sold by Celera Genomics, were offered by an underwriting group for which Morgan Stanley Dean Witter, Goldman, Sachs & Co., SG Cowen, ING Barings, and Bear Stearns & Co., Inc. are acting as representatives.

To: Biomaven who wrote (2768)	2/1/2001 9:08:53 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 52153

<<Indeed, leading genomics outfits saw their shares slide Wednesday: Millennium (MLNM:Nasdaq - news) dropped $2.75, or 5.2%, to $50.12, Incyte (INCY:Nasdaq - news) slipped 44 cents to $27.88 and Celera (CRA:NYSE - news) dropped $2.75, or 5.3%, to $49.01.>> What MLNM have to do with INCY and CLRA? Why they are constantly putting this bios together and comparing perfect bio-model with service-bios? Where are underwriters and analysts from last year? When they were selling ANYTHING to ANYONE at huge PREMIUM? Where is their voice now? Isn’t Lehman who have note in Dec. that excessive supply from the luck-up expiration (from IPO and SPO) will bring sector down in 1Q, and that they ARE consider THIS as BUYING OPORTUNITY? I guess, they need to be sure about BRING DOWN. <g> I am pissed off. Pissed off big time! When will HONEST and TRUTFUL analyst emerge from this Universe and put facts together, forever??? Miljenko